Navigation Links
New Treatment for Rosacea

A new, safe, and promising therapy option may be more effective in treating the 14 million Americans who suffer from rosacea, a chronic skin disease that causes persistent redness on the nose and cheeks.

Researchers applied a new formulation of azelaic acid gel to the faces of rosacea sufferers. //The new product contains 15 percent azelaic acid and is specifically made for rosacea. Typically it has a different formula and is used to treat acne. Many rosacea patients are generally treated with metronidazole gel, an antibiotic commonly used to treat infections of the small intestines and colon.

In a study, researchers compared the safety and efficacy of azelaic gel versus metronidazole gel in rosacea patients. They found the azelaic gel was better at reducing the number of lesions associated with rosacea and better at reducing the redness in patient’s faces than the metronidazole gel. Also, the metronidazole gel’s effectiveness plateaued after eight weeks, but the azelaic gel showed progressive effectiveness through the 15-week study.

Rosacea causes tiny blood vessels in the face to enlarge and become more visible through the skin. The vessels appear as tiny red lines, called telangiectasias. Rosacea can also cause pimples to occur, even though rosacea usually affects adults between ages 30 and 60. Study authors say the disease usually responds well to topical antimicrobials -- creams or gels that kill microorganisms like bacteria even though doctors have not been able to identify a microbiologic cause of rosacea. There is no cure for rosacea and if left untreated, it worsens.

Researchers say their study shows azelaic acid gel is consistently superior to metronidazole gel in improving the principal signs of rosacea, such as redness and inflammation. In the azelaic acid gel group, 78 percent of the patients rated their improvement as excellent or good, compared to 64 percent in the metronidazole gel grou.
'"/>




Page: 1

Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/22/2017)... ... August 22, 2017 , ... ... of unique masks and serums that perfectly fuse the beauty of naturally derived ... the 2017 Indie Beauty Expo on August 23rd & 24th in New York ...
(Date:8/22/2017)... ... August 22, 2017 , ... Western North ... at a popular international aesthetics conference for medical professionals about the positive impact ... health and his growing practice. , Dr. George K. Ibrahim shared ...
(Date:8/22/2017)... ... August 22, 2017 , ... ... announced recently the availability of a new professional fee E/M leveling calculator tool. ... service to the healthcare industry. E/M coding is complex which supports the need ...
(Date:8/22/2017)... ... August 22, 2017 , ... “To Walk Away”: ... a B17 bomber named Edward Koontz. “To Walk Away” is the creation of published ... has published over two hundred manuscripts in chemistry and religion, as well as four ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Covert Awakening”: Walid’s ... of published author, Julianne Hale, a consultant for the Intelligence Community. For ... focusing on the Near East region. Julianne has written hundreds of reports ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of the drug ... in the beginning stages of an IPO. The ... with the average cost of a prescription epilepsy drug being $450.00-$1200.00 for ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent ...
(Date:8/14/2017)... N.J. and PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI), a leading developer of adult stem ... the second quarter ending June 30, 2017. ... stages of preparing for our pivotal Phase 3 trial ... Chaim Lebovits , President and Chief Executive Officer of ...
(Date:8/8/2017)... AVIV, Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: ... immunology, today reports its financial results for the second ... achievements during the second quarter 2017 and to date: ... multiple clinical development programs for the Company,s lead project, ... 3 pivotal study with BL-8040 as novel stem cell ...
Breaking Medicine Technology: